aripiprazole lauroxil

Long-acting injectable antipsychotic • Brands: ARISTADA, ARISTADA INITIO

Last reviewed: 2025-12-30

General information

Class: Long-acting injectable antipsychotic
Common US brands: ARISTADA, ARISTADA INITIO
Long-acting injectable formulation available.
Therapeutic drug monitoring not routinely recommended; reference range 120–270 ng/mL.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Long-acting injectable prodrug of aripiprazole (D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism) designed for extended dosing intervals to support adherence in schizophrenia maintenance.

Metabolism & Half‑life

Metabolism: CYP2D6, CYP3A4
Half‑life: Steady-state range 1294–1373 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

Reference range: 120–270 ng/mL

View labelExact

Long‑acting injectable (LAI)

Aripiprazole lauroxil

Interval: q4–8wk (varies by strength)
Oral overlap: Yes — typically 21 days (unless using Initio loading)
Site: Deltoid or gluteal

Citations

Label Label DOI

Monitoring highlights

Sources

ARISTADA (aripiprazole lauroxil) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
ARISTADA INITIO (aripiprazole lauroxil) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 — Pharmacopsychiatry (2018)